Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma
ConclusionsThis case report highlights the importance of recognizing rare but serious adverse events related to immunotherapy and incorporation of appropriate tools for early identification and management in national cancer treatment guidelines.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | Immunotherapy | Melanoma | Men | Skin | Skin Cancer | Yervoy | Zinc